According to a new report from Intel Market Research, the global single-use bioprocessing system for vaccine production market was valued at USD 1.1 billion in 2024 and is projected to reach USD 1.94 billion by 2032, growing at a robust CAGR of 8.6% during the forecast period (2025β2032). This growth is propelled by increasing global vaccine demand, technological advancements in disposable bioprocessing equipment, and the need for flexible, cost-efficient manufacturing solutions.
Single-use bioprocessing systems (SUBS) are equipment solutions composed of polymer material components designed for single or limited-use biological processes. These systems feature disposable bioreactors, sensors and probes, filtration components, mixers, and containers that offer sterility, efficiency, and operational flexibility. They are primarily utilized in critical vaccine production processes including cell culture, protein expression, liquid filtration and purification, and real-time monitoring.
Unlike traditional stainless-steel systems requiring extensive cleaning validation, SUBS provide contamination-free environments essential for modern vaccine development. The technology has become particularly valuable for mRNA, viral vector, and recombinant protein vaccines, where maintaining product purity is paramount. Major pharmaceutical companies and contract manufacturers increasingly adopt these systems for their ability to reduce cross-contamination risks while accelerating production timelines.
π₯ Download Sample Report: Single-Use Bioprocessing System For Vaccine Production Market - View in Detailed Research Report
1. Global Vaccine Demand Surge and Pandemic Preparedness
The unprecedented need for rapid vaccine production during the COVID-19 pandemic demonstrated the critical advantages of single-use bioprocessing systems in vaccine manufacturing. With global vaccination programs expanding for diseases like HPV, influenza, and emerging pathogens, SUBS adoption continues to grow significantly. These systems offer 30-40% faster setup times compared to traditional stainless-steel bioreactors, enabling manufacturers to respond quickly to public health demands. The World Health Organization's expanded immunization schedule, now covering vaccines for 25 preventable diseases, creates sustained demand for flexible production technologies.
2. Cost Efficiency and Operational Flexibility
Single-use technologies reduce capital expenditures by approximately 60% by eliminating cleaning validation and sterilization costs associated with fixed equipment. For vaccine manufacturers operating in multiple markets, SUBS provides the agility to switch production between different vaccine types with minimal downtime. This operational flexibility proves particularly valuable as vaccine pipelines diversify to include various technological platforms, allowing manufacturers to repurpose facilities 50% faster than traditional setups during health emergencies.
Material limitations at scale: Most disposable bioreactors max out at 2,000 liters capacity, creating technological constraints for high-volume vaccine production
Supply chain vulnerabilities: Concentration of single-use plastics manufacturing in few geographic regions creates potential bottlenecks
Regulatory complexities: Transitioning validated processes requires complete requalification under stringent regulatory frameworks
The global shift toward regional vaccine manufacturing independence presents significant opportunities for SUBS providers. Governments in emerging markets are investing substantially to build localized production capacity, with single-use technologies accounting for over 60% of new facility designs due to lower infrastructure requirements and faster implementation timelines.
Technological convergence with Industry 4.0 solutions creates additional value through advanced sensor technologies enabling real-time monitoring of multiple critical process parameters. These digital enhancements address historical limitations while creating new revenue streams for equipment providers through data-as-a-service models.
Notably, industry leaders like Merck, Thermo Fisher Scientific, and Sartorius have announced expansion strategies focusing on:
Development of larger-scale disposable bioreactors
Enhanced polymer films with improved barrier properties
Integrated single-use platforms combining upstream and downstream processing
π₯ Download Sample PDF: Single-Use Bioprocessing System For Vaccine Production Market - View in Detailed Research Report
North America: Leads global market share owing to strong biopharmaceutical infrastructure, FDA support for innovative manufacturing technologies, and presence of major vaccine manufacturers
Europe: A mature market with emphasis on compliance with EMA standards and environmental directives, featuring strong manufacturing hubs in Germany and Switzerland
Asia-Pacific: Fastest-growing region driven by expanding vaccine manufacturing capabilities, particularly in China, and increasing government healthcare expenditure
Latin America and Middle East & Africa: Emerging markets with growing focus on building regional vaccine production capabilities through international partnerships
By Product Type
Disposable Bioreactors
Disposable Mixers
Disposable Filtration Systems
Disposable Bags and Containers
Tubing and Assemblies
By Application
Cell Culture
Filtration and Purification
Mixing and Storage
Process Monitoring and Control
By Vaccine Type
mRNA Vaccines
Viral Vector Vaccines
Subunit Vaccines
Inactivated Vaccines
By End User
Pharmaceutical and Biotechnology Companies
Contract Development and Manufacturing Organizations (CDMOs)
Research and Academic Institutions
π Get Full Report: Single-Use Bioprocessing System For Vaccine Production Market - View in Detailed Research Report
The market features intense competition among established pharmaceutical equipment giants and specialized bioprocessing solution providers. Merck KGaA and Thermo Fisher Scientific currently dominate the market, collectively holding significant revenue share through comprehensive product portfolios and recent strategic acquisitions.
The report provides in-depth competitive profiling of key players, including:
Merck KGaA
Thermo Fisher Scientific
Sartorius AG
Danaher Corporation (Cytiva)
Lonza Group
Fujifilm Diosynth Biotechnologies
Pall Corporation
Repligen Corporation
Global and regional market forecasts from 2025 to 2032
Strategic insights into technological developments and regulatory approvals
Market share analysis and SWOT assessments of key players
Pricing trends and supply chain analysis
Comprehensive segmentation by product type, application, vaccine type, and geography
π Get Full Report: Single-Use Bioprocessing System For Vaccine Production Market - View in Detailed Research Report
π₯ Download Sample PDF: Single-Use Bioprocessing System For Vaccine Production Market - View in Detailed Research Report
Intel Market Research is a leading provider of strategic intelligence, offering actionable insights in biotechnology, pharmaceuticals, and healthcare infrastructure. Our research capabilities include:
Real-time competitive benchmarking
Global clinical trial pipeline monitoring
Country-specific regulatory and pricing analysis
Over 500+ healthcare reports annually
Trusted by Fortune 500 companies, our insights empower decision-makers to drive innovation with confidence.
π Website: https://www.intelmarketresearch.com
π International: +1 (332) 2424 294
π Asia-Pacific: +91 9169164321
π LinkedIn: Follow Us